Currently out of the existing stock ratings of Salveen Richter, 146 are a HOLD (32.81%), 268 are a BUY (60.22%), 31 are a SELL (6.97%).

Salveen Richter

Work Performance Price Targets & Ratings Chart

Analyst Salveen Richter, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 64.26% that have a potential upside of 46.48% achieved within 269 days.

Salveen Richter’s has documented 846 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 08-Sep-2026.

Wall Street Analyst Salveen Richter

Analyst best performing recommendations are on ALLO (ALLOGENE THERAPEUTICS).
The best stock recommendation documented was for ALLO (ALLOGENE THERAPEUTICS) at 10/7/2021. The price target of $20 was fulfilled within 1 day with a profit of $4.38 (17.97%) receiving and performance score of 179.66.

Average potential price target upside

of $471.43 (27.41%) on ACOR (ACORDA THERAPEUTICS).
of $187.61 (28.75%) on REGN (REGENERON PHARMACEUTICALS).
of $89.29 (39.38%) on AMGN (AMGEN).

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ADPT Adaptive Biotechnologies Corp AGIO Agios Pharm ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals BLUE Bluebird bio BMRN Biomarin Pharmaceutical BPMC Blueprint Medicines Corp CRSP Crispr Therapeutics AG DNLI Denali Therapeutics DTIL Precision BioSciences GWPH GW Pharmaceuticals plc ICPT Intercept Pharmaceuticals INCY yte KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals MRNA Moderna MRTX Mirati Ther NTLA Intellia Therapeutics RETA Reata Pharmaceuticals SAGE Sage Therapeutic SANA Sana Biotechnology SGEN Seagen SRPT Sarepta Therapeutics TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals ARWR Arrowhead Pharmaceuticals ATRA Atara Biotherapeutics BIIB Biogen CNTA Centessa Pharmaceuticals PLC ADR PASG Passage Bio REGN Regeneron Pharmaceuticals RXRX Recursion Pharmaceuticals GILD Gilead Sciences RDUS Schnitzer Steel Industries AMGN Amgen QURE Uniqure NV TSVT 2Seventy Bio ADSK Autodesk FOLD Amicus Therapeutics IONS Ionis Pharmaceuticals LYEL Lyell Immunopharma ONCE Spark Therapeutics RARE Ultragenyx RCUS Arcus Biosciences SLDB Solid Biosciences LLC APLS Apellis Pharmaceuticals FDMT 4D Molecular Therapeutics RLAY Relay Therapeutics CLLS Cellectis SA SMMT Summit Therapeutics PLC IMNM Immunome SG Sweetgreen ELVN Enliven Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ananda Ghosh (HC WAINWRIGHT)

Buy Since 14-Dec-2025

$33

$12.32 (59.57%)

$37

Please subscribe to see extended stock data

Evan Seigerman (BMO)

Buy Since 16-Apr-2025

$34

$13.32 (64.41%)

$36

Please subscribe to see extended stock data

Jason Butler (JMP)

Buy Since 25-Nov-2019

$33

$12.32 (59.57%)

$36

Please subscribe to see extended stock data

David Hoang (DEUTSCHE BANK)

Buy Since 24-Sep-2025

$31

$10.32 (49.90%)

$38

Please subscribe to see extended stock data

Ami Fadia (NEEDHAM)

Buy Since 27-Feb-2024

$35

$14.32 (69.25%)

$41

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Salveen Richter most bullish on?

Potential upside of $35.25 has been obtained for ELVN (ENLIVEN THERAPEUTICS)

Which stock is Salveen Richter most reserved on?

Potential downside of -$78.88 has been obtained for MRNA (MODERNA)

What Year was the first public recommendation made by Salveen Richter?

On 2012